12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Influenza Vaccine Enhancement Patch: Completed Phase I enrollment

Intercell disclosed in its 4Q11 earnings that it completed enrollment of 300 healthy adults in an open-label, European Phase I trial comparing its Influenza VEP in combination with GlaxoSmithKline's H5N1 antigen...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >